Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points...

Area of Science:

• Cardiology
• Clinical Lipidology
• Cardiovascular Risk Assessment

Background:

• Cardiovascular disease (CVD) remains a leading cause of mortality globally.
• Statin therapy is a cornerstone in managing dyslipidemia and reducing CVD risk.
• The predictive value of triglycerides (TGs) in statin-treated patients requires further elucidation.

Purpose of the Study:

• To assess the predictive ability of in-trial triglyceride measurements for new cardiovascular events (CVEs).
• To evaluate the association between triglyceride levels and CVE risk in patients with established coronary heart disease receiving aggressive statin therapy.

Main Methods:

• Analysis of data from the Incremental Decrease in End Points through Aggressive Lipid Lowering (IDEAL) and Treating to New Targets (TNT) trials.
• Prospective assessment of CVEs occurring after the first year of treatment.
• Statistical analysis adjusting for covariates and assessing risk across triglyceride quintiles.

Main Results:

• Increasing triglyceride levels were significantly associated with a higher risk of CVEs (p <0.001).
• Patients in the highest TG quintile had a 63% higher rate of CVEs compared to the lowest quintile (HR 1.63).
• The predictive value of TGs diminished with the inclusion of other risk factors and was abolished when considering a comprehensive set of variables.

Conclusions:

• Even mildly elevated triglyceride levels are linked to an increased risk of recurrent CVEs in patients treated with statins.
• Triglycerides should be considered a valuable marker for cardiovascular risk assessment in statin-treated populations.
• The predictive power of TGs is influenced by other metabolic factors but remains significant even within the normal range.